Aging does not impact drug--drug interaction magnitudes with antiretrovirals.
Aged
Aged, 80 and over
Aging
Amlodipine
/ adverse effects
Anti-Retroviral Agents
/ therapeutic use
Antiretroviral Therapy, Highly Active
Atorvastatin
/ adverse effects
Cardiovascular Agents
/ adverse effects
Cardiovascular Diseases
/ drug therapy
Darunavir
/ adverse effects
Drug Interactions
Female
HIV Infections
/ drug therapy
Heterocyclic Compounds, 3-Ring
/ adverse effects
Humans
Male
Middle Aged
Oxazines
/ adverse effects
Piperazines
/ adverse effects
Pyridones
/ adverse effects
Rosuvastatin Calcium
/ adverse effects
Treatment Outcome
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 05 2020
01 05 2020
Historique:
pubmed:
7
2
2020
medline:
23
2
2021
entrez:
7
2
2020
Statut:
ppublish
Résumé
: The risk of drug-drug interactions (DDIs) is elevated in aging people living with HIV (PLWH) because of highly prevalent age-related comorbidities leading to more comedications. To investigate the impact of aging on DDI magnitudes between comedications (amlodipine, atorvastatin, rosuvastatin) and boosted darunavir, we conducted a clinical trial in aging PLWH aged at least 55 years. DDI magnitudes were comparable with those reported in young individuals supporting that the clinical management of DDIs in aging PLWH can be similar.
Identifiants
pubmed: 32028327
doi: 10.1097/QAD.0000000000002489
pii: 00002030-202005010-00017
doi:
Substances chimiques
Anti-Retroviral Agents
0
Cardiovascular Agents
0
Heterocyclic Compounds, 3-Ring
0
Oxazines
0
Piperazines
0
Pyridones
0
Amlodipine
1J444QC288
Rosuvastatin Calcium
83MVU38M7Q
Atorvastatin
A0JWA85V8F
dolutegravir
DKO1W9H7M1
Darunavir
YO603Y8113
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
949-952Références
Antiretroviral therapy cohort collaborationLife expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293–299.
Guaraldi G, Malagoli A, Calcagno A, Mussi C, Celesia B, Carli F, et al. The increasing burden and complexity of multimorbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65-74 years and more than 75 years. BMC Geriatr 2018; 18:99–109.
Stader F, Kinvig H, Penny MA, Battegay M, Siccardi M, Marzolini C. Physiologically based pharmacokinetic modelling to identify pharmackokinetic parameters driving drug exposure changes in the elderly. Clin Pharmacokinet 2019.
Stader F, Siccardi M, Battegay M, Kinvig H, Penny MA, Marzolini C. Repository describing an aging population to inform physiologically based pharmacokinetic models considering anatomical, physiological, and biological age-dependent changes. Clin Pharmacokinet 2019; 58:483–501.
Courlet P, Stader F, Guidi M, Saldanha SA, Stoeckle M, Cavassini M, et al. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging patients enrolled in the Swiss HIV Cohort Study. AIDS 2019; 34:103–108.
Courlet P, Spaggiari D, Desfontaine V, Cavassini M, Alves Saldanha S, Buclin T, et al. UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV. J Chromatogr B 2019; 1125:121733.
Glesby MJ, Aberg JA, Kendall MA, Fichtenbaum CJ, Hafner R, Hall S, et al. Adult AIDS Clinical Trials Group A5159 Protocol TeamPharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin Pharmacol Ther 2005; 78:143–153.
Mukherjee D, Zha J, Menon RM, Shebley M. Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model. J Pharmacokinet Pharmacodyn 2018; 45:443–456.
Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, et al. NIAID AIDS Clinical Trials GroupPharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16:569–577.
Pham P, La Porte C, Lee L, Van Heeswijk R, Sabo J, Elgadi M, et al. Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother 2009; 53:4385–4392.
Samineni D, Desai PB, Sallans L, Fichtenbaum CJ. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. J Clin Pharmacol 2012; 52:922–931.
Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O’Mara EM, Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998; 64:133–143.
Quinney SK, Haehner BD, Rhoades MB, Lin Z, Gorski JC, Hall SD. Interaction between midazolam and clarithromycin in the elderly. Br J Clin Pharmacol 2008; 65:98–109.
Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, et al. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 2003; 74:275–287.
Mathias A, West S, Hui J, Kearney B. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 2009; 85:64–70.
Annaert P, Ye Z, Stieger B, Augustijns P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica 2010; 40:163–176.
Kis O, Robillard K, Chan GN, Bendayan R. The complexities of antiretroviral drug–drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci 2010; 31:22–35.